[Comment] Aldosterone synthase inhibition in resistant hypertension: promises and unknowns

Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide, affecting an estimated 1·3 billion adults.1 Although most patients achieve adequate blood pressure control with two or three antihypertensive agents, up to 20% of cases remain uncontrolled, despite guideline-recommended combination therapy. After exclusion of pseudo-resistance, these patients are classified as having true resistant hypertension, a phenotype associated with elevated cardiovascular risk and a higher prevalence of secondary hypertension.